Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Chemotherapy|March 6, 2022
Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research GroupEwa Paszkiewicz-Kozik, Malgorzata Debowska, Natalia Jakacka, et al.
Virchows Archiv : an International Journal of Pathology|January 25, 2020
Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11Giorgio A Croci, Eva Hoster, Sílvia Beà, et al.
The Lancet. Haematology|February 5, 2025
Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNetVincent Ribrag, Dominique Bron, Grzegorz Rymkiewicz, et al.
Scientific Reports|June 22, 2022
High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow upJoanna Romejko-Jarosinska, Beata Ostrowska, Anna Dabrowska-Iwanicka, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 21, 2007
Differences in risk factors for breast cancer molecular subtypes in a population-based studyXiaohong R Yang, Mark E Sherman, David L Rimm, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 13, 2018
A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberrationGrzegorz Rymkiewicz, Beata Grygalewicz, Magdalena Chechlinska, et al.
Leukemia|July 7, 2026
Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histologyJonas Lippl, Sarah Reinke, Karoline Koch, et al.
Blood|December 21, 2018
The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphomaRabea Wagener, Julian Seufert, Francesco Raimondi, et al.
Haematologica|December 20, 2024
Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cellsAnna Torun, Aleksandra Zdanowicz, Nina Miazek-Zapala, et al.
International Journal of Cancer|May 10, 2007
Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysisMark E Sherman, David L Rimm, Xiaohong R Yang, et al.
Pageof 7